Esperion Therapeutics, Inc.

Sümbol: ESPR

NASDAQ

2.05

USD

Turuhind täna

-0.9875
P/E suhe
0.0209
PEG suhe
349.36M
MRK Cap
0.00%
DIV tootlus

Esperion Therapeutics, Inc. (ESPR) Finantsaruanded

Q: Mis on Esperion Therapeutics, Inc. (ESPR) koguvara?

Esperion Therapeutics, Inc. (ESPR) koguvara on .

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Esperion Therapeutics, Inc. (ESPR) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 341.627 M, mis on -0.107 % gowth. Kogu perioodi keskmine brutokasum on 326.092 M, mis on 0.442 %. Keskmine brutokasumi suhtarv on -22.771 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -0.273 %, mis on võrdne -0.369 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Esperion Therapeutics, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.170. Käibevara valdkonnas on ESPR aruandlusvaluutas 201.065. Märkimisväärne osa neist varadest, täpsemalt 82.248, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.341%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0, kui neid on, aruandlusvaluutas. See näitab erinevust -100.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 501.546 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 1.073%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud -454.994 aruandlusvaluutas. Selle aspekti aastane muutus on -0.660%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 48.494, varude hind on 65.62 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 0.06. Kontovõlad ja lühiajalised võlad on vastavalt 31.72 ja 36.38. Koguvõlg on 540.95, netovõlg on 458.7. Muud lühiajalised kohustused moodustavad 62.72, mis lisandub kohustuste kogusummale 660.79. Lõpuks hinnatakse viidatud aktsia 0, kui see on olemas.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2002	2000
balance-sheet.row.cash-and-short-term-investments	497.89	82.2	124.8	208.9	305	166.1	37	34.5	38.2	77.3	85	60.1	6.5	1.6	44.9	70.3	70.2	5.9
balance-sheet.row.short-term-investments	17.43	0	42.1	50.4	0	34.7	99	165.7	173.4	134.9	20.8	3.5	0	0	4.4	0	0	0
balance-sheet.row.net-receivables	168.33	48.5	33.7	22.9	12.4	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.inventory	202.09	65.6	35.2	34.4	16.1	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-current-assets	20.89	4.7	9.9	62.8	24.8	10.9	6.6	3.7	2	2.1	0.9	0.6	0.6	0.3	0.4	1	1.1	0.1
balance-sheet.row.total-current-assets	902.02	201.1	246.7	329	345.9	211.7	142.6	203.9	213.6	214.4	106.8	60.6	7.1	1.9	45.3	71.3	71.3	6
balance-sheet.row.property-plant-equipment-net	11.3	4.7	1.2	2.6	7.3	2.7	0.5	0.4	0.7	0.8	0.8	0.1	0.1	0.3	3	3.3	2.5	2
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.1	3.1	0	0
balance-sheet.row.intangible-assets	0.22	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	0	3.5	0
balance-sheet.row.goodwill-and-intangible-assets	0.22	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	3.1	3.1	3.5	0
balance-sheet.row.long-term-investments	0	0	42.1	50.4	0	34.7	99.3	239.2	204.3	215.2	56.5	17.5	0	0	0	0	0	0
balance-sheet.row.tax-assets	0	0	0	-50.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	-3.72	0	-42.1	50	-7.4	-34.7	-99	-165.7	-173.4	-134.9	-20.8	0	0	0	0	0.6	0.5	0
balance-sheet.row.total-non-current-assets	11.52	4.7	1.3	52.6	7.4	2.7	0.8	73.9	31.6	81.2	36.6	17.7	0.2	0.3	6.1	7.1	6.5	2
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	913.55	205.8	247.9	381.6	353.3	214.4	143.5	277.8	245.2	295.6	143.3	78.3	7.3	2.2	51.4	78.3	77.9	8
balance-sheet.row.account-payables	99.56	31.7	23	17.6	52	28.9	44.9	20.4	4.6	0.7	2	2.2	0.5	0.7	1.7	2.9	3.9	1.4
balance-sheet.row.short-term-debt	38.29	36.4	0.4	1.4	2.6	0.5	0	1	1.7	1.6	0.6	0	15.2	0	1.1	0.9	0.7	0.5
balance-sheet.row.tax-payables	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	1288.3	501.5	260.6	258.8	182.8	1.1	0	0	1	2.7	4.3	0	7.5	6.9	7.7	5.5	3	2.3
Deferred Revenue Non Current	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	285.83	62.7	65.4	48.7	37.8	34.6	19.4	11.7	9.2	3.3	2.7	2	0.3	0.6	2.2	2.6	2.5	1
balance-sheet.row.total-non-current-liabilities	1983.59	504.6	479.4	505.2	355.3	128.4	0	0	1	2.7	4.3	0	7.5	6.9	7.7	5.5	3	2.3
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	9.46	3	1	1.9	6	1.6	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	2480.18	660.8	571.7	578.5	449.4	194.5	64.3	33.1	16.6	8.3	9.8	4.2	24.7	8.2	12.7	11.8	10.2	5.2
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	78293.9	24	24	0	0	0	0
balance-sheet.row.common-stock	0.42	0.1	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-5895.67	-1549.3	-1340	-1106.4	-838.8	-695.3	-598.1	-396.3	-229.2	-154.2	-104.4	-68.1	-42	-30.2	-94	-65.3	-40.4	-12.8
balance-sheet.row.accumulated-other-comprehensive-income-loss	0	0	0	0	0	0	-0.3	-0.8	-0.2	-0.5	-0.1	0	-1.2	-1	-3.7	-2.4	-1.3	-0.5
balance-sheet.row.other-total-stockholders-equity	3256.52	1094.2	-0.1	0	0	-0.1	0.3	641.8	458	441.9	238	-78151.7	1.8	1.2	136.4	134.2	109.3	16.1
balance-sheet.row.total-stockholders-equity	-2638.73	-455	-1340	-1106.4	-838.8	-695.3	-598.1	244.7	228.6	287.3	133.6	74.1	-17.4	-6.1	38.7	66.5	67.7	2.8
balance-sheet.row.total-liabilities-and-stockholders-equity	-158.55	205.8	-768.3	-527.8	-389.4	-500.8	-533.8	277.8	245.2	295.6	143.3	78.3	7.3	2.2	51.4	78.3	77.9	8
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	-2638.73	-455	-1340	-1106.4	-838.8	-695.3	-598.1	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	-158.55	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	17.43	0	84.2	100.9	0	69.3	99.3	239.2	204.3	215.2	56.5	21.1	0	0	4.4	0	0	0
balance-sheet.row.total-debt	1329.61	540.9	260.9	260.2	185.4	1.6	0	1	2.7	4.3	4.9	0	22.8	6.9	8.8	6.3	3.7	2.8
balance-sheet.row.net-debt	849.15	458.7	136.2	51.3	-119.6	-164.6	-37	-33.4	-35.4	-73	-80.1	-56.5	16.3	5.3	-31.7	-63.9	-66.5	-3.1

Rahavoogude aruanne

Esperion Therapeutics, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 0.225 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 65.97, mis tähistab 57.333 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 8.68 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli 42500000.000. See on 4.244 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 0.16, 0, -15.51, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 0, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2002	2000
cash-flows.row.net-income	-209.25	-209.2	-233.7	-269.1	-143.6	-97.2	-201.8	-167	-75	-49.8	-36.4	-26.1	-11.7	-10.8	-28.7	-24.9	-27.6	-10.7
cash-flows.row.depreciation-and-amortization	0.16	0.2	0.5	0.6	0.5	0.3	0.3	0.3	0.3	0.2	0.2	0.1	0.1	0.2	-1.3	-2	-2	-0.7
cash-flows.row.deferred-income-tax	-17.56	36.5	0	-2.6	-0.1	-0.2	0	0.3	1	0.7	0.2	2.5	0.1	0.1	0	0	0	0
cash-flows.row.stock-based-compensation	11.96	12	15.2	24.3	28.4	25.9	24	18.6	16	12.7	3.7	1.2	0.1	0.1	0	0	0	0
cash-flows.row.change-in-working-capital	13.68	13.7	-3.4	-52.5	-4.3	-7.3	29.2	16.5	10	-2.1	0.3	3.2	-0.8	0.8	-0.5	-1.1	3	1.9
cash-flows.row.account-receivables	-14.77	-14.8	-10.8	-10.5	-10.7	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-30.42	-30.4	-0.8	-18.3	-16.1	0	0	0	0	0	0	0	0	0	0	0	0	-2.6
cash-flows.row.account-payables	8.68	8.7	5.6	-34.1	23.1	-16.1	24.4	15.8	3.9	-1.3	-0.3	1.8	-0.2	0.6	-1.2	-0.8	2.6	1.3
cash-flows.row.other-working-capital	50.18	50.2	2.6	10.4	-0.5	8.8	4.7	0.7	6.1	-0.8	0.6	1.5	-0.6	0.2	0.8	-0.2	0.4	3.1
cash-flows.row.other-non-cash-items	65.52	11.5	46.5	35.5	33.8	8.1	-0.2	0	0	0.1	0	0.9	1.5	0.6	3.9	5.2	8.7	1.6
cash-flows.row.net-cash-provided-by-operating-activities	-135.49	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	0	0	0	0	-13.4	-1	-0.2	0	-0.1	-0.3	-0.9	0	0	0	-1.2	-2	-1.3	-1.6
cash-flows.row.acquisitions-net	0	0	0	0	12.5	-65.2	0	0	0	0	0	0	0	0	0	0	-0.2	0
cash-flows.row.purchases-of-investments	0	0	-59.9	-50.5	-4.4	-34.3	-25.5	-219.6	-197.2	-280.6	-48.1	-24.7	0	0	-37.2	0	0	0
cash-flows.row.sales-maturities-of-investments	42.5	42.5	68	0	39.1	99.5	166.1	183.7	207.4	120.8	12.4	3.5	0	0.5	32.9	0	0	0
cash-flows.row.other-investing-activites	42.5	0	0	0	-12.5	65.2	0	0	0	0	0	0.2	0	0	0	-0.1	-0.5	0
cash-flows.row.net-cash-used-for-investing-activites	42.5	42.5	8.1	-50.5	21.4	64.2	140.4	-35.9	10.1	-160.1	-36.6	-21	0	0.5	-5.5	-2.1	-2	-1.6
cash-flows.row.debt-repayment	-15.51	-15.5	-58.2	-0.8	-296.1	-124.4	-1	-1.7	-1.6	-0.6	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-issued	13.52	66	90.8	218.7	6.6	11.8	0	164	0	190	91.7	72.2	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	-0.02	0	0	0	-55	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	-302.7	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-financing-activites	53.81	0	-50.2	50.3	848.9	248.8	11.7	1.2	0	1.2	5.4	16.9	15.7	6.7	1.4	25	84.1	2.8
cash-flows.row.net-cash-used-provided-by-financing-activities	50.46	50.5	32.6	268.2	201.7	136.2	10.7	163.5	-1.6	190.5	97.1	89.1	15.8	6.7	1.4	25	84.1	2.8
cash-flows.row.effect-of-forex-changes-on-cash	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	-0.1	0.2	0
cash-flows.row.net-change-in-cash	-42.53	-42.5	-134.1	-46.1	137.9	130.1	2.5	-3.7	-39.2	-7.7	28.5	50	4.9	-1.8	-29.8	0.1	64.3	-6.6
cash-flows.row.cash-at-end-of-period	480.46	82.2	124.8	258.9	305	167.1	37	34.5	38.2	77.3	85	56.5	6.5	1.6	40.5	70.3	70.2	5.9
cash-flows.row.cash-at-beginning-of-period	522.99	124.8	258.9	305	167.1	37	34.5	38.2	77.3	85	56.5	6.5	1.6	3.4	70.3	70.2	5.9	12.5
cash-flows.row.operating-cash-flow	-135.49	-135.5	-174.8	-263.8	-85.2	-70.3	-148.6	-131.3	-47.7	-38.2	-32	-18.1	-10.8	-9.1	-26.6	-22.8	-18	-7.9
cash-flows.row.capital-expenditure	0	0	0	0	-13.4	-1	-0.2	0	-0.1	-0.3	-0.9	0	0	0	-1.2	-2	-1.3	-1.6
cash-flows.row.free-cash-flow	-135.49	-135.5	-174.8	-263.8	-98.5	-71.3	-148.8	-131.3	-47.8	-38.5	-32.9	-18.1	-10.8	-9.1	-27.7	-24.8	-19.3	-9.4

Kasumiaruande rida

Esperion Therapeutics, Inc. tulud muutusid võrreldes eelmise perioodiga 0.541%. ESPR brutokasum on teatatud 72.9. Ettevõtte tegevuskulud on 228.47, mille muutus võrreldes eelmise aastaga on 0.200%. Kulud amortisatsioonikulud on 0.16, mis on -0.938% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 228.47, mis näitab 0.200% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab 0.133% kasvu võrreldes eelmise aastaga. Tegevustulu on -155.56, mis näitab -0.133% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -0.273%. Eelmise aasta puhaskasum oli -209.25.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2002	2000
income-statement-row.row.total-revenue	116.33	116.3	75.5	78.4	227.5	148.4	184.5	0	0	0	0	4977	0	0	0	0	0	0
income-statement-row.row.cost-of-revenue	43.27	43.4	27	14.2	2.4	175.6	0	0	0	0	0	0	0	0	0	0	0.8	0.7
income-statement-row.row.gross-profit	73.06	72.9	48.5	64.2	225.2	-27.2	184.5	0	0	0	0	4977	0	0	0	0	-0.8	-0.7
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	86.11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	29.82	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	15.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	22.52	5.3	2.7	4	0.5	4.1	2.8	2.2	1.5	0.8	0.1	0.2	-0.1	-0.1	0	0	5	3.2
income-statement-row.row.operating-expenses	248.79	228.5	228	291	346.6	241.5	204.6	169	76.2	50	36.2	22.8	10.2	10.2	29.2	29.3	26.8	11.7
income-statement-row.row.cost-and-expenses	271.9	271.9	255	305.2	348.9	241.5	204.6	169	76.2	50	36.2	22.8	10.2	10.2	29.2	29.3	27.6	12.4
income-statement-row.row.interest-income	5.11	4.8	2.6	0.1	0.6	4	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.interest-expense	-0.09	59	56.8	46.4	22.7	8.1	0.1	0.2	0.4	0.5	0.3	0.9	1.5	0.6	0	0	0	0
income-statement-row.row.selling-and-marketing-expenses	15.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-53.69	-53.7	-54.2	-42.4	-22.2	-4.1	2.8	2.2	1.5	0.8	0.1	-2.4	-0.1	-0.1	-0.7	0.3	-3.8	0
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	22.52	5.3	2.7	4	0.5	4.1	2.8	2.2	1.5	0.8	0.1	0.2	-0.1	-0.1	0	0	5	3.2
income-statement-row.row.total-operating-expenses	-53.69	-53.7	-54.2	-42.4	-22.2	-4.1	2.8	2.2	1.5	0.8	0.1	-2.4	-0.1	-0.1	-0.7	0.3	-3.8	0
income-statement-row.row.interest-expense	-0.09	59	56.8	46.4	22.7	8.1	0.1	0.2	0.4	0.5	0.3	0.9	1.5	0.6	0	0	0	0
income-statement-row.row.depreciation-and-amortization	1.36	0.2	2.7	4	0.5	4.1	0.3	0.3	0.3	0.2	0.2	0.1	0.1	0.2	-1.3	-2	-2	-0.7
income-statement-row.row.ebitda-caps	-154.28	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-155.56	-155.6	-179.5	-226.7	-121.4	-93.1	-204.6	-169	-76.2	-50	-36.2	-22.8	-10.2	-10.2	-27.9	-27.3	-27.6	-12.4
income-statement-row.row.income-before-tax	-209.25	-209.2	-233.7	-269.1	-143.6	-97.2	-201.8	-167	-75	-49.8	-36.4	-26.1	-11.7	-10.8	-28.7	-24.9	-31.4	0
income-statement-row.row.income-tax-expense	27.42	0	54.2	49.7	22.6	11.9	2.9	2.1	1.7	1.1	0.2	1.1	1.4	0.5	2.1	0.5	4.1	-0.3
income-statement-row.row.net-income	-236.75	-209.2	-287.8	-318.8	-166.2	-109	-201.8	-167	-75	-49.8	-36.4	-26.1	-11.7	-10.8	-28.7	-24.9	-27.6	-10.7